Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

However, the drug’s effects on overall energy levels may vary from person to person. Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

In December 2023, the company stopped the development of the twice-daily version of danuglipron due to high rates of ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...